These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

553 related articles for article (PubMed ID: 27745982)

  • 1. Salivary Cytokine Levels and Oral Mucositis in Head and Neck Cancer Patients Treated With Chemotherapy and Radiation Therapy.
    Bossi P; Bergamini C; Miceli R; Cova A; Orlandi E; Resteghini C; Locati L; Alfieri S; Imbimbo M; Granata R; Mariani L; Iacovelli NA; Huber V; Cavallo A; Licitra L; Rivoltini L
    Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):959-966. PubMed ID: 27745982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 2 study of docetaxel, cisplatin, and concurrent radiation for technically resectable stage III-IV squamous cell carcinoma of the head and neck.
    Inohara H; Takenaka Y; Yoshii T; Nakahara S; Yamamoto Y; Tomiyama Y; Seo Y; Isohashi F; Suzuki O; Yoshioka Y; Sumida I; Ogawa K
    Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):934-41. PubMed ID: 25832686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study evaluating the addition of cetuximab to the concurrent delivery of weekly carboplatin, paclitaxel, and daily radiotherapy for patients with locally advanced squamous cell carcinomas of the head and neck.
    Suntharalingam M; Kwok Y; Goloubeva O; Parekh A; Taylor R; Wolf J; Zimrin A; Strome S; Ord R; Cullen KJ
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1845-50. PubMed ID: 21601372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer.
    Haddad R; Sonis S; Posner M; Wirth L; Costello R; Braschayko P; Allen A; Mahadevan A; Flynn J; Burke E; Li Y; Tishler RB
    Cancer; 2009 Oct; 115(19):4514-23. PubMed ID: 19634161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective Study of Cetuximab, Carboplatin, and Radiation Therapy for Patients With Locally Advanced Head and Neck Squamous Cell Cancer Unfit for Cisplatin.
    Corry J; Bressel M; Fua T; Herschtal A; Solomon B; Porceddu SV; Wratten C; Rischin D
    Int J Radiat Oncol Biol Phys; 2017 Jul; 98(4):948-954. PubMed ID: 28483336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Weekly cetuximab concurrent with IMRT aggravated radiation-induced oral mucositis in locally advanced nasopharyngeal carcinoma: Results of a randomized phase II study.
    Xu T; Liu Y; Dou S; Li F; Guan X; Zhu G
    Oral Oncol; 2015 Sep; 51(9):875-9. PubMed ID: 26163437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apoptotic and inflammation markers in oral mucositis in head and neck cancer patients receiving radiotherapy: preliminary report.
    Xanthinaki A; Nicolatou-Galitis O; Athanassiadou P; Gonidi M; Kouloulias V; Sotiropoulou-Lontou A; Pissakas G; Kyprianou K; Kouvaris J; Patsouris E
    Support Care Cancer; 2008 Sep; 16(9):1025-33. PubMed ID: 18197435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of radiotherapy and chemotherapy on the risk of mucositis during intensity-modulated radiation therapy for oropharyngeal cancer.
    Sanguineti G; Sormani MP; Marur S; Gunn GB; Rao N; Cianchetti M; Ricchetti F; McNutt T; Wu B; Forastiere A
    Int J Radiat Oncol Biol Phys; 2012 May; 83(1):235-42. PubMed ID: 22104358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of low-level laser therapy on chemoradiotherapy-induced oral mucositis and salivary inflammatory mediators in head and neck cancer patients.
    Oton-Leite AF; Silva GB; Morais MO; Silva TA; Leles CR; Valadares MC; Pinezi JC; Batista AC; Mendonça EF
    Lasers Surg Med; 2015 Apr; 47(4):296-305. PubMed ID: 25824475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral mucositis prevention by low-level laser therapy in head-and-neck cancer patients undergoing concurrent chemoradiotherapy: a phase III randomized study.
    Gouvêa de Lima A; Villar RC; de Castro G; Antequera R; Gil E; Rosalmeida MC; Federico MH; Snitcovsky IM
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):270-5. PubMed ID: 21163585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Non-surgical combined modality treatments for laryngeal organ preservation in advanced hypopharyngeal carcinoma].
    Zhang X; Wang J; Wu W; Ma L; Liu M; Zhao F; Huang D
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2014 Jul; 49(7):558-63. PubMed ID: 25257270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concurrent cisplatin and radiation versus cetuximab and radiation for locally advanced head-and-neck cancer.
    Koutcher L; Sherman E; Fury M; Wolden S; Zhang Z; Mo Q; Stewart L; Schupak K; Gelblum D; Wong R; Kraus D; Shah J; Zelefsky M; Pfister D; Lee N
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):915-22. PubMed ID: 20947269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of photobiomodulation on the severity of oral mucositis and molecular changes in head and neck cancer patients undergoing radiotherapy: a study protocol for a cost-effectiveness randomized clinical trial.
    Martins AFL; Nogueira TE; Morais MO; Oton-Leite AF; Valadares MC; Batista AC; Freitas NMA; Leles CR; Mendonça EF
    Trials; 2019 Feb; 20(1):97. PubMed ID: 30709370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival of patients with head and neck cancer treated with definitive radiotherapy and concurrent cisplatin or concurrent cetuximab: A Surveillance, Epidemiology, and End Results-Medicare analysis.
    Xiang M; Holsinger FC; Colevas AD; Chen MM; Le QT; Beadle BM
    Cancer; 2018 Dec; 124(23):4486-4494. PubMed ID: 30332498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of locally advanced carcinomas of head and neck with intensity-modulated radiation therapy (IMRT) in combination with cetuximab and chemotherapy: the REACH protocol.
    Habl G; Jensen AD; Potthoff K; Uhl M; Hof H; Hajda J; Simon C; Debus J; Krempien R; Münter MW
    BMC Cancer; 2010 Nov; 10():651. PubMed ID: 21108850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperfractionated accelerated radiation therapy (HART) of 70.6 Gy with concurrent 5-FU/Mitomycin C is superior to HART of 77.6 Gy alone in locally advanced head and neck cancer: long-term results of the ARO 95-06 randomized phase III trial.
    Budach V; Stromberger C; Poettgen C; Baumann M; Budach W; Grabenbauer G; Marnitz S; Olze H; Wernecke KD; Ghadjar P
    Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):916-24. PubMed ID: 25670541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma.
    Brizel DM; Murphy BA; Rosenthal DI; Pandya KJ; Glück S; Brizel HE; Meredith RF; Berger D; Chen MG; Mendenhall W
    J Clin Oncol; 2008 May; 26(15):2489-96. PubMed ID: 18487568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Analysis of the Risk Factors for Severe Oral Mucositis in Head and Neck Cancer after Chemoradiotherapy with S-1].
    Nagatani A; Ogawa Y; Sunaga T; Tomura K; Naito Y; Fujii N; Okabe T; Hashimoto T; Kogo M; Sasaki T
    Yakugaku Zasshi; 2017; 137(2):221-225. PubMed ID: 28154335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel model of megavoltage radiation-induced oral mucositis in hamsters: Role of inflammatory cytokines and nitric oxide.
    Moura JF; Mota JM; Leite CA; Wong DV; Bezerra NP; Brito GA; Lima V; Cunha FQ; Ribeiro RA
    Int J Radiat Biol; 2015 Jun; 91(6):500-9. PubMed ID: 25758466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the NCI-CTCAE version 4.0 and version 3.0 in assessing chemoradiation-induced oral mucositis for locally advanced nasopharyngeal carcinoma.
    Liu YJ; Zhu GP; Guan XY
    Oral Oncol; 2012 Jun; 48(6):554-9. PubMed ID: 22289637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.